|
|
           
|
|
|
|
|
|
|
|
 
|
|
Rv3795 More about Rv3795 on TBDB.org More about Rv3795 on TubercuList |
Display all mutations or select a bar from the histogram above to examine in greater detail |
| Rv3795: Codons 325 to 349: 12 mutations (high confidence mutations are highlighted in yellow) | |||||||||||||||
| Primary reference | Polymorphism | Nucleotide position | Codon position | Amino acid | Time period | Origin | Molecular detection method | Gene coverage | Resistance pattern | MIC | Susceptibility testing method | R/Total isolates | R/S isolates with mutation | Additional mutations | High confidence support |
| Ramaswamy SV AAC 2000 | GAT/TAT | 982 | 328 | Asp/Tyr | Published 2000 | USA, Russia | Sequencing | Whole gene | E | 30ug/ml | BACTEC 460, agar diffusion method | 75/108 | 1/0 | Ala201Thr in embA, Tyr334His in embB. | - |
| Ramaswamy SV AAC 2000 | GAT/GGT | 983 | 328 | Asp/Gly | Published 2000 | USA, Russia | Sequencing | Whole gene | E | 10-50ug/ml | BACTEC 460, agar diffusion method | 75/108 | 1/0 | - | - |
| Plinke C AAC 2006 | GAT/GTG | 983-984 | 328 | Asp/Val | 2001 | Germany | Sequencing | ERDR | EHR | N.S. | Proportion method, BACTEC 460 | 101/159 | 1/0 | None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1. | - |
| Escalante P TuberLung Dis 1998 | del A | 983 | - | Frameshift | "Published 1998; isolates collected 1995-1996" | Peru | Sequencing | ERDR | E | N.S. | Proportion method | 40146 | 1/0 | None in region amplified (see Gene coverage). | - |
| Sreevatsan S AAC 1997 | TTC/GTC | 988 | 330 | Phe/Val | Published 1997 | USA, Mexico, Europe, Yemen, the Philippines, Japan, India | PCR-SSCP, Sequencing | Whole gene | E | 40ug/ml | BACTEC 460, agar diffusion method | 69/99 | 1/0 | - | - |
| Srivastava S JMM 2009 | GGC/CGT | 991-993 | 331 | Gly/Arg | Published 2009 | India | Sequencing | Whole gene | ER | 16ug/ml | Proportion method, E-Test | 44/44 | 1/0 | "embB V360M, G374V, G401S; embC I297T; embR D223E" | - |
| Lee HY YonseiMedJ 2002 | GAT/TAT | 991 | 331 | Asp/Tyr | Published 2002 | Korea | Sequencing | ERDR | E | 4ug/ml | Proportion method | 21/26 | 1/0 | None in region amplified (see Gene coverage). | - |
| Plinke C AAC 2006 | TGG/CTG | 994-995 | 332 | Trp/Leu | 2001 | Germany | Sequencing | ERDR | EHR | N.S. | Proportion method, BACTEC 460 | 101/159 | 1/0 | None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1. | - |
| Sugawara I Jpn J Infect Dis 2005 | TAT/CAT | 997 | 333 | Tyr/His | - | - | - | - | - | - | - | - | - | - | - |
| Ramaswamy SV AAC 2000 | TAC/CAC | 1000 | 334 | Tyr/His | Published 2000 | USA, Russia | Sequencing | Whole gene | E | 30ug/ml | BACTEC 460, agar diffusion method | 75/108 | 1/0 | Ala201Thr in embA, Asp328Tyr in embB. | - |
| Escalante P TuberLung Dis 1998 | AGT/ACT | 1040 | 347 | Ser/Thr | "Published 1998; isolates collected 1995-1996" | Peru | Sequencing | ERDR | E | N.S. | Proportion method | 40146 | 1/0 | None in region amplified (see Gene coverage). | - |
| Srivastava S JMM 2009 | AGT/ATT | 1040 | 347 | Ser/Ile | Published 2009 | India | Sequencing | Whole gene | EHR | 4ug/ml | Proportion method, E-Test | 44/44 | 1/0 | "embB E368D, R460L; embC I297T; embR R230W, I396T" | - |
Disclaimer: These are all putative mutations found in drug resistant clinical TB isolates. No a priori decisions have been made as to whether these mutations are causally related to resistance or possible secondary mutations. |
|
© 2010 Andreas Sandgren | Supported by the Swedish Research Council | Contact Database Curator |